United States Patent 7,081,252: Oxybutynin Transdermal Patent Scope, Claims, Expiration, and Competitive Landscape

U.S. Patent No. 7,081,252 covers transdermal oxybutynin treatment for overactive bladder that limits anticholinergic adverse effects by producing a defined plasma exposure ratio between oxybutynin and its metabolite, principally N-desethyloxybutynin. The patent also covers patches configured to produce that pharmacokinetic profile.

The patent issued on July 25, 2006, and is expired. Based on its earliest effective nonprovisional filing date, the expected patent-term endpoint was November 27, 2022. The patent therefore does not currently block generic or follow-on transdermal oxybutynin commercialization. Its principal historical relevance was to Oxytrol and related oxybutynin transdermal systems.

What does U.S. Patent 7,081,252 protect?

The patent protects two related categories:

A method of treating overactive bladder with a transdermal oxybutynin patch.
An article of manufacture consisting of a transdermal oxybutynin patch that produces a specified oxybutynin-to-metabolite AUC ratio.

The central technical concept is avoidance of the high first-pass hepatic metabolism associated with oral oxybutynin. Oral dosing produces substantial N-desethyloxybutynin exposure, which is associated with anticholinergic adverse effects such as dry mouth. Transdermal administration reduces metabolite formation relative to oxybutynin exposure.

The claims do not cover every oxybutynin patch. They require the patch, when used under the claimed conditions, to produce a particular plasma AUC ratio.

Patent identification

Field	Detail
Patent	U.S. Patent No. 7,081,252
Title	Methods of reducing adverse effects of oxybutynin therapy
Inventor and owner history	Associated with Noven Pharmaceuticals and its oxybutynin transdermal technology
Filing priority	November 27, 2001
Issue date	July 25, 2006
Technology	Transdermal oxybutynin for overactive bladder
Primary product relevance	Oxytrol and related oxybutynin transdermal systems
Expected expiration	November 27, 2022
Current status	Expired
Patent type	Method-of-treatment and article-of-manufacture claims

The controlling patent term is generally 20 years from the earliest effective nonprovisional filing date for applications filed after June 8, 1995, subject to patent-term adjustment, terminal disclaimers, and other statutory adjustments. The patent is no longer an enforceable barrier to market entry.

How do the independent claims operate?

Claims 1 and 2 are method claims. Claims 13 and 14 are article-of-manufacture claims.

Method claims

Claim 1 requires:

a human subject;
overactive bladder;
oxybutynin treatment;
administration through a transdermal patch;
administration for approximately 24 to 96 hours;
an oxybutynin-to-metabolite plasma AUC ratio of approximately 0.5:1 to 5:1; and
minimization of an anticholinergic or antimuscarinic adverse drug experience.

Claim 2 is similar but uses “up to 96 hours” rather than the more specific 24-to-96-hour range.

The method claims therefore combine a disease indication, a route of administration, a duration, a pharmacokinetic result, and a clinical outcome.

Article claims

Claims 13 and 14 cover a physical transdermal patch containing oxybutynin. The patch must provide the claimed AUC ratio after administration and must minimize an anticholinergic or antimuscarinic adverse drug experience.

The article claims do not require a particular patch architecture, adhesive, reservoir, backing layer, or permeation-enhancer concentration. They are outcome-based claims tied to the patch’s pharmacokinetic performance.

What are the key limitations in claims 1 through 24?

Claim group	Subject matter	Limitation
1	Treatment method	24 to 96 hours; AUC ratio 0.5:1 to 5:1
2	Treatment method	Up to 96 hours; AUC ratio 0.5:1 to 5:1
3	Dependent method	AUC ratio 1:1 to 5:1
4	Dependent method	AUC ratio 0.8:1 to 1.5:1
5	Dependent method	Metabolite is N-desethyloxybutynin
6	Dependent method	R-, S-, or combined N-desethyloxybutynin
7	Dependent method	Oxybutynin is an R/S mixture
8	Dependent method	Oxybutynin is R-oxybutynin
9	Dependent method	Administration is 72 to 96 hours
10	Dependent method	72-hour administration
11	Dependent method	84-hour administration
12	Dependent method	96-hour administration
13	Article of manufacture	Patch, 24 to 96 hours, AUC ratio 0.5:1 to 5:1
14	Article of manufacture	Patch, up to 96 hours, AUC ratio 0.5:1 to 5:1
15	Dependent article	AUC ratio 1:1 to 5:1
16	Dependent article	AUC ratio 0.8:1 to 1.5:1
17	Dependent article	Metabolite is N-desethyloxybutynin
18	Dependent article	R-, S-, or combined metabolite
19	Dependent article	R/S oxybutynin mixture
20	Dependent article	R-oxybutynin
21	Dependent article	72 to 96 hours
22	Dependent article	72 hours
23	Dependent article	84 hours
24	Dependent article	96 hours

The dependent claims narrow the claims mainly by pharmacokinetic ratio, stereochemistry, metabolite identity, and patch duration. They do not add a specific adhesive formulation or manufacturing process.

What AUC ratio does the patent require?

The broadest ratio is approximately 0.5:1 to 5:1 for oxybutynin relative to an oxybutynin metabolite.

The most commercially relevant narrower range is approximately 0.8:1 to 1.5:1 under claims 4 and 16. Claims 5 and 17 identify N-desethyloxybutynin as the metabolite. Claims 6 and 18 further cover its R and S enantiomers.

The ratio is a plasma pharmacokinetic relationship:

[ \text{AUC ratio} = \frac{\text{oxybutynin plasma AUC}}{\text{metabolite plasma AUC}} ]

The patent does not define infringement solely by the nominal amount of oxybutynin in a patch. A patch containing the same nominal dose as Oxytrol could fall outside the claims if it does not produce the claimed exposure ratio. Conversely, a different formulation could implicate the claims if it produces the same claimed pharmacokinetic result.

How strong are the claims from an infringement perspective?

The patent’s historical claim scope was meaningful but technically dependent. Its strength depended on proving the pharmacokinetic result and, for the method claims, proving the required clinical use.

Strengths

The claims reach the pharmacokinetic advantage of transdermal oxybutynin rather than only a particular patch structure.
The claims cover both treatment methods and the patch as an article.
The claims include broad AUC-ratio ranges.
The claims cover racemic oxybutynin and R-oxybutynin.
The claims address the commercially important 72-hour patch-use period.

Limitations

The AUC ratio must be established through pharmacokinetic testing.
The claims depend on the identity of the metabolite being measured.
Patient characteristics, sampling schedules, assay methods, and steady-state conditions can affect the ratio.
The “minimizing” adverse-experience limitation may require clinical or comparative evidence.
The method claims require treatment of a human with overactive bladder, not merely manufacture or sale of a patch.
“Optionally includes a permeation enhancer” does not require a permeation enhancer, so that phrase does not materially narrow the claims.

Because the patent has expired, these issues now have historical rather than blocking significance. They remain relevant to freedom-to-operate analyses involving past sales, damages periods, or contractual representations concerning earlier market entry.

What formulations are protected by U.S. Patent 7,081,252?

The claims are formulation-neutral at a high level. They can cover a transdermal patch containing oxybutynin in a matrix, reservoir, adhesive, or other delivery configuration if the patch produces the claimed pharmacokinetic profile.

The patent does not require:

a specific polymer;
a specified adhesive;
a named permeation enhancer;
a fixed oxybutynin loading;
a particular patch area;
a particular backing layer;
a specific release rate;
a specific brand name; or
a particular manufacturing process.

The patent does not independently claim oral tablets, capsules, immediate-release oxybutynin, extended-release oxybutynin, oxybutynin gel, or injectable oxybutynin.

Permeation enhancers

The claims state that a permeation enhancer may be present. Because the language is optional, a formulation with a permeation enhancer and a formulation without one can both fall within the claims if the other limitations are satisfied.

This substantially broadens the formulation coverage but leaves the claims dependent on actual pharmacokinetic performance.

Does the patent cover R-oxybutynin?

Yes. Claims 8 and 20 expressly cover R-oxybutynin.

The patent also covers:

a mixture of R-oxybutynin and S-oxybutynin;
N-desethyloxybutynin generally; and
R-, S-, or combined N-desethyloxybutynin.

The R-oxybutynin limitations are dependent claims. A product using racemic oxybutynin may implicate the broader claims without needing to satisfy the R-oxybutynin-specific claims.

What was the Orange Book status of U.S. Patent 7,081,252?

U.S. Patent 7,081,252 was associated with the Orange Book patent listing for Oxytrol, the oxybutynin transdermal system approved under NDA 021351. The related Orange Book landscape also included earlier transdermal oxybutynin patents, including U.S. Patent No. 6,743,211.

Orange Book listing did not extend the patent beyond its statutory term. Once the patent expired, it ceased to create a current patent-based obstacle to an ANDA applicant or an OTC competitor. FDA Orange Book listings identify patents submitted by sponsors, but they do not determine patent validity or enforceability. The Orange Book also does not replace a full patent-family and litigation search.

When did U.S. Patent 7,081,252 lose exclusivity?

The patent lost patent exclusivity no later than November 27, 2022, based on the reported 20-year term from the November 27, 2001 filing date. The patent is therefore expired as of 2025.

Separate FDA exclusivities must be distinguished from patent rights:

Oxytrol was approved as a prescription product in 2003.
The FDA later approved nonprescription marketing for Oxytrol for Women in 2013.
FDA regulatory exclusivity periods associated with those approvals have also expired.
Patent expiration and FDA exclusivity expiration are separate legal events.

The patent’s expiration means a generic manufacturer can no longer be blocked by this patent alone, although regulatory requirements, manufacturing capability, product liability, trademarks, and other patents may remain relevant.

What other patents were important to transdermal oxybutynin?

The principal historical patent estate included earlier transdermal oxybutynin patents and the pharmacokinetic patent at issue.

Patent	General subject matter	Historical relevance	Current position
U.S. 5,834,010	Transdermal administration of oxybutynin	Early transdermal oxybutynin platform	Expired
U.S. 6,743,211	Transdermal delivery of oxybutynin	Patch delivery and product protection	Expired
U.S. 7,081,252	Reduced adverse effects through oxybutynin/metabolite AUC ratio	Pharmacokinetic and treatment-use protection	Expired

U.S. Patent 5,834,010 and U.S. Patent 6,743,211 were more closely associated with the transdermal delivery platform itself. U.S. Patent 7,081,252 focused on the relationship between oxybutynin and metabolite exposure and the resulting adverse-effect profile.

A complete current freedom-to-operate review must also check continuation applications, terminal disclaimers, patent-term adjustment, foreign counterparts, and patents owned by suppliers or competitors. The three patents above represent the principal U.S. historical estate relevant to the claimed technology.

Were there Paragraph IV challenges to the patent?

A Paragraph IV certification would have been relevant to an ANDA seeking approval for a generic prescription oxybutynin transdermal system while U.S. 7,081,252 or another Orange Book-listed patent remained active.

The commercial significance of any Paragraph IV challenge depended on:

which patent claims were certified against;
whether the ANDA product produced the claimed AUC ratio;
whether the ANDA applicant used a 72-hour or another administration period;
whether the product label included the overactive-bladder indication;
whether a lawsuit was filed within 45 days; and
whether the patent was still enforceable when FDA approval became effective.

After November 2022, a Paragraph IV certification against U.S. 7,081,252 no longer creates a current patent-delay risk because the patent is expired. Historical litigation records should be reviewed separately for damages, settlement, or launch-date analysis. No active Paragraph IV barrier from this patent remains.

Which companies challenged or commercialized transdermal oxybutynin?

The commercial ecosystem included:

Noven Pharmaceuticals, associated with development of the transdermal oxybutynin technology;
Watson Pharmaceuticals, later associated with Actavis and Allergan, in prescription commercialization;
Merck, associated with U.S. OTC commercialization of Oxytrol for Women; and
generic manufacturers pursuing oxybutynin transdermal systems after patent and regulatory barriers declined.

The original commercial product was Oxytrol, an oxybutynin transdermal system delivering approximately 3.9 mg of oxybutynin per day. The product was designed for multi-day use, consistent with the 72-hour duration expressly addressed by claims 9, 10, 21, and 22.

Because oxybutynin is a small molecule, there is no biosimilar pathway. Follow-on products proceed through generic or other small-molecule regulatory pathways, principally an ANDA for a therapeutically equivalent product or an alternative NDA pathway where an ANDA is unavailable.

What generic launch risks existed?

Before patent expiration, a generic patch faced several risks:

Patent infringement based on the AUC ratio.
Claim scope covering the 72-hour use period.
Difficulty designing around a pharmacokinetic limitation without changing the product’s clinical performance.
Potential Orange Book litigation and a 30-month FDA stay after timely patent litigation.
Need to demonstrate bioequivalence for a transdermal system.
Manufacturing challenges involving adhesive uniformity, drug crystallization, skin permeation, patch adhesion, and release kinetics.

After expiration, the patent-related risks changed materially. The remaining barriers became regulatory and commercial rather than exclusivity-based. These include demonstrating bioequivalence, securing reliable patch manufacturing, obtaining sufficient distribution, satisfying OTC labeling requirements where applicable, and competing with oral oxybutynin, gels, and other overactive-bladder therapies.

How does this patent compare with oral oxybutynin patents?

U.S. Patent 7,081,252 is narrower in dosage form but broader in functional outcome than a conventional composition patent.

Issue	U.S. 7,081,252	Oral oxybutynin patent
Dosage form	Transdermal patch	Tablet, capsule, or oral formulation
Core protection	AUC relationship and reduced adverse effects	Composition, release profile, or formulation
Clinical indication	Overactive bladder	May cover the same or different indication
Key evidence	Plasma pharmacokinetics and adverse-effect reduction	Formulation or bioequivalence evidence
Design-around route	Alter exposure ratio, duration, or delivery system	Change release matrix, dose, excipients, or dosage form
Current patent status	Expired	Depends on the specific patent

The patent is not a general patent on oxybutynin treatment. Its relevance is limited to transdermal administration that produces the defined pharmacokinetic relationship.

What manufacturing and intellectual-property barriers remain?

Although U.S. 7,081,252 is expired, manufacturing barriers remain substantial for transdermal systems.

A commercial patch must control:

drug loading and content uniformity;
adhesive performance;
skin permeation;
crystallization;
residual solvent levels;
patch adhesion during bathing and movement;
release over the intended wear period;
packaging and moisture protection; and
stability over shelf life.

These technical requirements can create practical barriers even without an enforceable patent. They do not restore exclusivity, but they can limit the number of viable competitors.

Trademark rights in “Oxytrol” and related branding also remain separate from patent rights. A generic manufacturer cannot use the brand name merely because the underlying patents have expired.

What is the current commercial exposure?

The historical revenue exposure was linked to Oxytrol prescription and OTC sales. Public company filings generally did not report the product as a separately material revenue category after portfolio changes and OTC commercialization. Current exposure to U.S. Patent 7,081,252 is therefore primarily historical.

The most commercially exposed products were:

Oxytrol prescription transdermal systems;
Oxytrol for Women OTC products; and
generic or authorized-generic oxybutynin patches launched after patent expiration.

The patent no longer supports a premium based on exclusivity. Commercial value now depends on brand recognition, OTC distribution, payer coverage, manufacturing economics, and clinical tolerability.

Key Takeaways

U.S. Patent 7,081,252 covers transdermal oxybutynin treatment and patches that produce an oxybutynin-to-metabolite AUC ratio of approximately 0.5:1 to 5:1.
The principal metabolite is N-desethyloxybutynin.
The claims cover 24-to-96-hour and up-to-96-hour administration, with specific dependent claims for 72, 84, and 96 hours.
Claims 4 and 16 narrow the ratio to approximately 0.8:1 to 1.5:1.
Claims 8 and 20 cover R-oxybutynin.
The patent historically supported protection for Oxytrol and related transdermal oxybutynin products.
The patent expired in November 2022.
No current patent exclusivity remains under U.S. 7,081,252.
The patent does not cover oral oxybutynin, oxybutynin gel, or every oxybutynin patch without regard to pharmacokinetic performance.
Transdermal manufacturing, bioequivalence, adhesive performance, and branding remain practical market barriers.
Because oxybutynin is a small molecule, biosimilar analysis is inapplicable.

FAQs About U.S. Patent 7,081,252

Is U.S. Patent 7,081,252 still enforceable?

No. The patent expired in 2022 and does not provide current enforceable patent exclusivity.

Does the patent cover all oxybutynin patches?

No. The patch must satisfy the claimed administration and pharmacokinetic limitations, including the oxybutynin-to-metabolite AUC ratio.

Does U.S. 7,081,252 cover oxybutynin gel?

No. The issued claims require a transdermal patch. They do not expressly cover oxybutynin gel products.

Can a generic manufacturer launch a 72-hour oxybutynin patch?

The patent no longer prevents such a launch. The manufacturer must still satisfy FDA requirements, including applicable bioequivalence, quality, labeling, and manufacturing standards.

Was U.S. 7,081,252 a drug-substance patent?

No. It was a method-of-treatment and article-of-manufacture patent focused on transdermal delivery and the resulting oxybutynin/metabolite exposure ratio.

References

U.S. Patent and Trademark Office. (2006). U.S. Patent No. 7,081,252: Methods of reducing adverse effects of oxybutynin therapy.
U.S. Patent and Trademark Office. (1998). U.S. Patent No. 5,834,010: Transdermal administration of oxybutynin.
U.S. Patent and Trademark Office. (2004). U.S. Patent No. 6,743,211: Transdermal delivery of oxybutynin.
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2003). Oxytrol: Oxybutynin transdermal system, prescribing information.
U.S. Food and Drug Administration. (2013). FDA approves first over-the-counter treatment for overactive bladder.
United States Code. (2023). 35 U.S.C. §§ 154, 271, 282.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	488233	⤷ Start Trial
Australia	2001253782	⤷ Start Trial
Australia	2003287377	⤷ Start Trial
Australia	2003294239	⤷ Start Trial
Australia	2010200418	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,081,252

Summary for Patent: 7,081,252